Literature DB >> 8655711

beta hCG as a prognostic marker in adenocarcinoma of the prostate.

M T Sheaff1, J E Martin, D F Badenoch, S I Baithun.   

Abstract

AIMS: To assess the importance of immunohistological detection of beta-human chorionic gonadotrophin (beta hCG) in localised prostatic adenocarcinoma with regard to prognosis and clinical applications.
METHODS: Eighty consecutive cases of clinically localised adenocarcinoma of the prostate were studied retrospectively. Immunohistological analysis on formalin fixed, paraffin wax embedded prostate tissue from transurethral resections was related to clinical outcome and survival. Prognosis was also related to tumour grade.
RESULTS: beta hCG was detected in 12 cases. Nine of these patients were found to have metastases (75%) at follow up and 11 (92%) were dead within 18 months. There was no correlation with grade and prognosis in this group. Of the 68 beta hCG negative cases, 21 had developed metastases (31%) and 25 (37%) had died within 18 months. In the beta hCG negative group there was an association between histological grade and survival.
CONCLUSION: The demonstration of beta hCG in prostatic adenocarcinoma identifies a group of patients with poor prognosis, irrespective of histological grade. This additional information will be extremely valuable in the subsequent clinical management of such patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8655711      PMCID: PMC500461          DOI: 10.1136/jcp.49.4.329

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  23 in total

1.  Production of beta-human chorionic gonadotropin by prostatic adenocarcinoma and transitional cell carcinoma of the upper urinary tract.

Authors:  V M Shah; J Newman; J Crocker; G N Antonakopoulos; C R Chapple; M J Collard
Journal:  Br J Exp Pathol       Date:  1987-12

2.  Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate.

Authors:  P A Abrahamsson; L B Wadström; J Alumets; S Falkmer; L Grimelius
Journal:  Pathol Res Pract       Date:  1987-06       Impact factor: 3.250

3.  Placental proteins and their subunits as tumor markers in prostatic carcinoma.

Authors:  L E Broder; B D Weintraub; S W Rosen; M H Cohen; F Tejada
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

4.  Ectopic production of human chorionic gonadotropin (hCG) by neoplasms: the value of measurements of immunoreactive hCG in the urine as a screening procedure.

Authors:  P D Papapetrou; N P Sakarelou; H Braouzi; P Fessas
Journal:  Cancer       Date:  1980-05-15       Impact factor: 6.860

5.  Calcitonin-secreting carcinomas of the prostate. An immunohistochemical and ultrastructural analysis.

Authors:  F Fetissof; P Bruandet; B Arbeille; J Penot; Y Marboeuf; J Le Roux; D Guilloteau; J L Beaulieu
Journal:  Am J Surg Pathol       Date:  1986-10       Impact factor: 6.394

6.  Human chorionic gonadotropin in human neoplastic cells.

Authors:  L M McManus; M A Naughton; A Martinez-Hernandez
Journal:  Cancer Res       Date:  1976-09       Impact factor: 12.701

7.  Human chorionic gonadotropin detected in urinary concentrates from patients with malignant tumors of the testis, prostate, bladder, ureter and kidney.

Authors:  K Fukutani; J M Libby; W B Panko; P T Scardino
Journal:  J Urol       Date:  1983-01       Impact factor: 7.450

8.  Human chorionic gonadotropin in colorectal carcinoma. An immunohistochemical study.

Authors:  E Campo; A Palacin; C Benasco; E Quesada; A Cardesa
Journal:  Cancer       Date:  1987-05-01       Impact factor: 6.860

9.  On the effects of oestrogen in the male. Some effects of different oestrogenic substances in rats and men with prostatic carcinoma.

Authors:  L Daehlin
Journal:  Scand J Urol Nephrol Suppl       Date:  1985

10.  Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.

Authors:  D M Purnell; B M Heatfield; B F Trump
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

View more
  17 in total

1.  beta hCG as a prognostic marker in prostatic adenocarcinoma.

Authors:  P Furness
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

2.  The prognostic significance of beta human chorionic gonadotrophin and its metabolites in women with cervical carcinoma.

Authors:  R A Crawford; R K Iles; P G Carter; C J Caldwell; J H Shepherd; T Chard
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

3.  Human chorionic gonadotropin β induces cell motility via ERK1/2 and MMP-2 activation in human glioblastoma U87MG cells.

Authors:  Zongwen Li; Lianlian Du; Chunliu Li; Wei Wu
Journal:  J Neurooncol       Date:  2012-12-13       Impact factor: 4.130

4.  Human chorionic gonadotrophin beta expression in malignant Barrett's oesophagus.

Authors:  Anne Couvelard; François Paraf; Dominique Vidaud; Sylvie Dubois; Michel Vidaud; Jean-François Fléjou; Claude Degott
Journal:  Virchows Arch       Date:  2004-08-10       Impact factor: 4.064

5.  TGF-β-induced hCG-β regulates redox homeostasis in glioma cells.

Authors:  Fahim Ahmad; Sadashib Ghosh; Sanchari Sinha; Shanker Datt Joshi; Veer Singh Mehta; Ellora Sen
Journal:  Mol Cell Biochem       Date:  2014-10-10       Impact factor: 3.396

6.  The free beta-subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma.

Authors:  K Hotakainen; B Ljungberg; A Paju; T Rasmuson; H Alfthan; U-H Stenman
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

7.  Transgenesis-mediated reproductive dysfunction and tumorigenesis: effects of immunological neutralization.

Authors:  Ruchi Sachdeva; Neetu Bhardwaj; Ilpo Huhtaniemi; Usha Aggrawal; Swatantra Kumar Jain; Rana Zaidi; Om Singh; Rahul Pal
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

8.  Dedifferentiated Liposarcoma of the Retroperitoneum with Extensive Leiomyosarcomatous Differentiation and beta-Human Chorionic Gonadotropin Production.

Authors:  Michael J Russell; Frederick L Flynt; Allyson L Harroff; Oluwole Fadare
Journal:  Sarcoma       Date:  2008

9.  Gonadotropin-mediated chemoresistance: Delineation of molecular pathways and targets.

Authors:  Suchismita Sahoo; Poonam Singh; Beneeta Kalha; Om Singh; Rahul Pal
Journal:  BMC Cancer       Date:  2015-11-25       Impact factor: 4.430

10.  Sex differences in the MB49 syngeneic, murine model of bladder cancer.

Authors:  Shai White-Gilbertson; Megan Davis; Christina Voelkel-Johnson; Laura M Kasman
Journal:  Bladder (San Franc)       Date:  2016-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.